Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study
Frontiers in Oncology · 28.04.2025 · 15
DOI: 10.3389/fonc.2025.1590779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.04.2025. Verfasst von Jian Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Sou…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The emergence of the C797S mutation in the epidermal growth factor receptor (EGFR) significantly limits the efficacy of covalent inhibitors in treating non-small cell lung cancer (NSCLC). This study aimed to design and evaluate novel allosteric inhibitors targeting the C797S mutant EGFR using advanced in silico methodologies.
Methods
Utilizing scaffold hopping techniques, a library of compounds was generated based on the known allosteric inhibitor EAI045. Virtual screening identified 44 top-scoring compounds with strong binding affinities for the C797S mutant EGFR. Molecular docking studies evaluated binding interactions, while the MM-GBSA method assessed binding free energies. Additionally, pharmacokinetic properties were analysed using Lipinski’s rule of five, and the most promising compound, MK1, underwent molecular dynamics simulations followed by in-vitro assessment Results A total of 12 heterocyclic scaffolds were derived from EAI045, and 44 top-scoring compounds were identified through virtual screening and MM-GBSA analysis. MK1 demonstrated the highest docking score and a ΔG_bind of -29.36 kcal/mol, with strong interactions involving residues such as LYS728 and MET793. MD simulations over 100 ns confirmed the stability of the MK1-EGFR complex, with RMSD values stabilizing post-50 ns and RMSF values consistently below 3 Å. In-vitro assays validated MK1’s potent anticancer activity, showing significant cytotoxicity against C797S mutant cell lines, with IC50 values lower than the standard comparator. Additional pharmacokinetic profiling indicated MK1 adhered to Lipinski’s Rule of Five with no violations, highlighting its drug-like properties.
Conclusion
The findings highlight MK1 as a promising candidate for the treatment of NSCLC harbouring the C797S mutation, providing valuable insights for future drug design and development strategies targeting mutant EGFR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, Chin…
- Department of Chemical Technology, Dr Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, India.
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States.
- Department Paediatric Research, Shenzhen Children's Hospital, Shenzhen, China.
- Department of Pharmacy, DY Patil University, Kolhapur, Maharashtra, India.
Zitieren
APA
Wang, J., Yuan, F., Kendre, M., He, Z., Dong, S., Patil, A., & Padvi, K. (2025). Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1590779
Vancouver
Wang J, Yuan F, Kendre M, He Z, Dong S, Patil A, et al. Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1590779
BibTeX
@article{Wang2025,
author = {Wang, Jian and Yuan, Feiyang and Kendre, Mahadevi and He, Zhijin and Dong, Shaowei and Patil, Abhinandan and Padvi, Kausing},
title = {Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1590779}
}
EUVIMED